Seawolf Therapeutics Launches with $100M Funding to Advance DNA Therapeutics
4 days ago
Seawolf Therapeutics has secured $100 million in Series A funding to develop DNA-based drugs using specialized lipid nanoparticles. Major investors include Novartis, Eli Lilly, and CRISPR Therapeutics, supporting the safer delivery method over viral vectors.